Form D · Biotechnology

SAB Biotherapeutics, Inc.

Miami Beach, FL · CIK 0001833214

Offering snapshot reported Aug 5, 2025 · SEC filing

Reported sold
$175M
Offering amount: $175M
Investors reported
17
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jul 21, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 5, 2025Initial$175,000,000No comparison17SEC filing
Oct 16, 2023Initial$7,500,000No comparison13SEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$10.5M
Finders' fees
$0
Form D file number
021-553778

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Leerink Partners LLC39011
UBS SECURITIES LLC7654
Oppenheimer & Co. Inc.249
Chardan Capital Markets, LLC120128

Source: Form D, filed Aug 5, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Russell Beyer Executive
Katie Ellias Director
Scott Giberson Director
Christine Hamilton Director
David Link Director
Erick Lucera Director
Andrew Moin Director
William Polvino Director
Samuel Reich Director, Executive
Jay Skyler Director
Jeffrey Spragens Director
Eddie Sullivan Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
777 W 41st St Suite 401
Miami Beach, FL, 33140